The effects of trimetazidine on lipid peroxidation in patients with end-stage renal disease

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 30, Issue 10, 2008, Pages 757-760

  Aygen, Bilge ^a   Celiker, Huseyin ^a   Dogukan, Ayhan ^a   Ilhan, Necip ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

End stage renal disease; Malondialdehyde; Trimetazidine

Indexed keywords

MALONALDEHYDE; OXYGEN RADICAL; TRIMETAZIDINE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LIPID PEROXIDATION; MALE; MORTALITY; OXIDATIVE STRESS; TREATMENT DURATION;

ADULT; ANTIOXIDANTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS; TRIMETAZIDINE; YOUNG ADULT;

EID: 63649140238     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2008.30.10.1316831     Document Type: Article

References (29)

1. Schmidtmann, S., Muller, M., von Baehr, R., Precht, K. Changes of antioxidative homeostasis in patients on chronic haemodialysis. Nephrol Dial Transplant 1991, 6(Suppl. 3): 71-4.
2. Usberti, M., Gerardi, G.M., Gazzotti, R.M. et al. Oxidative stress and cardiovascular disease in dialyzed patients. Nephron 2002, 91(1): 25-33,
3. Inagi, R., Miyata, T. Oxidative protein damage with carbohydrates and lipids in uremia: 'Carhonyl stress'. Blood Purif 1999, 17(2-3): 95-8.
4. Miyata, T., Fu, M.X., Kurokawa, K., van Yperselc de Strihou, C., Thorpe, S.R., Baynes, J.W. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia? Kidney Int 1998, 54(4): 1290-5.
5. Morena, M., Delhose, S., Dupuy, A.M., Canaud, B., Cristol, J.P. Overproduction of reactive oxygen species in end-stage renal disease patients: A potential component of hemodialysis-associated inflammation. Hemodial Int 2005, 9(1): 37-46.
6. Massy, Z.A., Nguyen-Khoa, T. Oxidative stress and chronic renal failure: Markers and management. J Nephrol 2002, 15(4): 336-41.
7. Foley, R.N., Parfrey, P.S., Sarnak, M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(5, Suppl. 3): S112-9.
8. Berry, C., Brosnan, M.J., Fennell, J., Hamilton, C.A., Dominiczak, A.F. Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens 2001, 10(2): 247-55.
9. Kundhal, K., Lok, C.E. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract 2005, 101(2): c47-52.
10. Shah, S.V., Baliga, R., Rajapurkar, M., Fonseca, V.A. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007, 18(1): 16-28.
11. Loughrey, C.M., Young, I.S., Lightbody, J.H., McMaster, D., McNamee, P.T., Trimble, E.R. Oxidative stress in haemodialysis. QJM 1994, 87(11): 679-83.
12. Ruiz-Meana, M. Trimetazidine, oxidative stress, and cell injury during myocardial reperfusion. Rev Esp Cardiol 2005, 58(8): 895-7.
13. Maridonneau-Parini, I., Harpey, C. Trimetazidine protects the human red blood cell against oxygen free radical damage. Cardiovasc Drugs Ther 1990, 4(Suppl. 4): 818-9.
14. Renaud, J.F. Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988, 1(6): 677-86.
15. Satoh, K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1978, 90(1): 37-43.
16. Yagi, K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol 1998, 108: 101-6.
17. Locatelli, F., Canaud, B., Eckardt, K.U., Stenvinkel, P., Wanner, C., Zoccali, C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18(7): 1272-80.
18. Matkovics, B., Laszlo, A., Varga, S.I., Gal, G., Solymosi, T. Changes and correlations of antioxidant enzymes, lipid peroxidation and serum neutral lipids due to haemodialysis treatment in chronic uraemic patients. Int Urol Nephrol 1988, 20(5): 559-64.
19. Martin-Mateo, M.C., del Canto-Jafiez, E., Barrero-Martinez, M.J. Oxidative stress and enzyme activity in ambulatory renal patients undergoing continuous peritoneal dialysis. Ren Fail 1998, 20(1): 117-24.
20. Richard, M.J., Arnaud, J., Jurkovitz, C. et al. Trace elements and lipid peroxidation abnormalities inpatients with chronic renal failure. Nephron 1991, 57(1): 10-5.
21. Cathcart, M.K., Morel, D.W., Chisolm, G.M. 3rd. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol 1985, 38(2): 341-50.
22. Morel, D.W., Hessler, J.R., Chisolm, GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983, 24(8): 1070-6.
23. Harpey, C., Clauser, P., Labrid, C., Freyria, J.L., Poirier, J.P. Trimetazidine, a cellular antiischemic agent. Cardiovasc Drug Rev 1989, 6: 292-312.
24. Kantor, P.F., Lucien, A., Kozak, R., Lopaschuk, G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000, 86(5): 580-8.
25. Stanley, W.C., Marzilli, M. Metabolic therapy in the treatment Of ischaemic heart disease: The pharmacology of trimetazidine. Fundam Clin Pharmacol 2003, 17(2): 133-45.
26. Rossi, A., Lavanchy, N., Martin, J. Antiischemic effects of trimetazidine: 31P-NMR spectroscopy study in the isolated rat heart. Cardiovasc Drugs Ther 1990, 4(Suppl. 4): 812-3.
27. Tselepis, A., Doulias, P., Lourida, E., Glantzounis, G., Tsimoyiannis, E., Galaris, D. Trimetazidine protects low-density lipoproteins from oxidation and cultured cells exposed to H(2)O(2) from DNA damage. Free Radic Biol Med 2001, 30(12): 1357-64.
28. Fantini, E., Demaison, L., Sentex, E., Grynberg, A., Athias, P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994, 26(8): 949-58.
29. Wierzbicki, P., Cwetsch, A., Fijalkowski, P., Wankowicz, Z. Influence of trimetazidine on echocardiography parameters and free radical stress index in coronary artery disease and end-stage renal failure patients treated by hemodialysis: Preliminary communication. Pol Arch Med Wewn 1999, 102(1): 589-94.